Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Tislelizumab, Cetuximab, and Chemotherapy for Recurrent OSCC
NCT06728618Phase 2Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Dec 2024
- Primary completion
- May 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in oral squamous cell carcinoma (OSCC), oropharyngeal squamous cell carcinoma (OPSCC), sponsored by Zhongshan Hospital, Fudan University. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
oral squamous cell carcinoma (OSCC)oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on NCT06728618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06728618.